{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atorvastatin+Calcium+Tablets",
    "query": {
      "intervention": "Atorvastatin Calcium Tablets"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 80,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atorvastatin+Calcium+Tablets&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T04:29:47.820Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00303277",
      "title": "Do HMG CoA Reductase Inhibitors Affect Abeta Levels?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Aging"
      ],
      "interventions": [
        {
          "name": "simvastatin",
          "type": "DRUG"
        },
        {
          "name": "pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 35,
      "start_date": "2002-08",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2010-04-13",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303277"
    },
    {
      "nct_id": "NCT05641753",
      "title": "Cholesterol Lowering and Residual Risk in Diabetes, Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Evolocumab Cartridge",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin Calcium Tablets",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe Tablets",
          "type": "DRUG"
        },
        {
          "name": "18F-FDG",
          "type": "DRUG"
        },
        {
          "name": "Angiocatheter 20IV",
          "type": "DEVICE"
        },
        {
          "name": "J-Wire",
          "type": "DEVICE"
        },
        {
          "name": "GlycoCheck Glycocalyx Measurement Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 125,
      "start_date": "2022-12-06",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05641753"
    },
    {
      "nct_id": "NCT01763866",
      "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2067,
      "start_date": "2013-01-15",
      "completion_date": "2013-12-04",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763866"
    },
    {
      "nct_id": "NCT01732718",
      "title": "Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-09",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732718"
    },
    {
      "nct_id": "NCT04379999",
      "title": "Atorvastatin ± Aspirin in Lynch Syndrome Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "Atorvastatin 20mg",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin 20mg AND Aspirin 325 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2018-09-10",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379999"
    },
    {
      "nct_id": "NCT01806324",
      "title": "A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "HL040XC",
          "type": "DRUG"
        },
        {
          "name": "Losartan + Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HanAll BioPharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "19 Years to 50 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2012-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01806324"
    },
    {
      "nct_id": "NCT00639158",
      "title": "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "Coronary Heart Disease",
        "Combined (Atherogenic) Dyslipidemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ABT-335",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 543,
      "start_date": "2008-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-06-13",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 118,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00639158"
    },
    {
      "nct_id": "NCT00570752",
      "title": "Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vascular Diseases"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "BMS-582949",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Statin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2008-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 17,
      "location_summary": "Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more",
      "locations": [
        {
          "city": "Chiefland",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570752"
    },
    {
      "nct_id": "NCT04765137",
      "title": "Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Atorvastatin Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "60 Years to 95 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-05-21",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04765137"
    },
    {
      "nct_id": "NCT01644188",
      "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for ezetimibe)",
          "type": "DRUG"
        },
        {
          "name": "Lipid Modifying Therapy (LMT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 720,
      "start_date": "2012-08",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-09-02T04:29:47.820Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644188"
    }
  ]
}